NOVEMBER 9, 2016: CONNECTIVE TISSUE ONCOLOGY SOCIETY (CTOS), LISBON, PORTUGAL

“Factors Impacting the Establishment of Individual Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX) Mouse Models: A UCLA Sarcoma Program Prospective Clinical Trial” by Eckardt et al.

By Tara Russell, MD, MPH
UCLA General Surgery Resident
This study demonstrates a very high (82%) establishment rate for PDOX in HG-STS patients who were treatment naïve at the time of surgical excision.

Comments are closed.